Or. Admin. Code § 852-080-0030 - Conditions of Formulary Application
The following conditions apply to the formulary of pharmaceutical agents in 852-080-0020 and 852-080-0025:
(1) Optometric physicians certified for
Topical Therapeutic Pharmaceutical Agents (TPA), Nontopical Therapeutic
Pharmaceutical Agents (AT) or Nontopical Therapeutic Pharmaceutical Agents with
Injections (ATI) may use, administer, and prescribe any and all
over-the-counter pharmaceutical agents.
(2) Optometric physicians certified for
topical TPA use may use, administer and prescribe topical agents in Categories
1-16.
(3) Optometric physicians
certified for nontopical TPA use have the designation "AT" or "ATI" printed on
their licenses, and may use, administer and prescribe topical and nontopical
agents in Categories 1-24 as indicated for procedures that are permitted under
OAR Chapter 852, Division 20 Standards of Optometric Practice.
(4) Glaucoma Treatment:
(a) Optometric physicians treating a patient
with antiglaucoma medication must consult with an ophthalmologist if:
(A) The glaucoma progresses despite the use
of two glaucoma medications;
(B)
More than two medications are required to control the glaucoma; or
(C) A secondary glaucoma develops;
(b) Glaucoma is considered to be
progressing if, in comparison to prior examinations, there is a reproducible
worsening of the patient's visual field as measured by standard threshold
testing or if there is a worsening of the patient's optic nerve as measured by
direct observation or standard imaging technology or by rising eye pressure
despite the use of two or more medications;
(c) Glaucoma is considered to be under
control if target eye pressure, individualized for each patient, is maintained
with no abnormal glaucomatous progression; and
(d) A combination medication that contains
two pharmacologic agents is considered one medication.
(5) Optometric physicians certified for
nontopical TPA must consult with a doctor of medicine or doctor of osteopathy,
licensed under ORS Chapter 677, before extending treatment with nontopical
corticosteriods or Schedule III analgesics beyond seven days.
(6) Optometric physicians should be diligent
in preventing the diversion of drugs for illegitimate purposes. Upon
application, active status licensees are granted access to the Oregon
Prescription Drug Monitoring Program of the Oregon Health Authority to research
controlled substance information on their patients; under ORS Chapter 431, fees
for the program are required to be collected at the time of annual active
license renewal by the Board and allow doctors to register and use the program
at no additional charge.
(7)
Optometric physicians may not use, administer or prescribe agents classified
principally as anti-neoplastics.
(8) Optometric physicians may use or
administer pharmaceutical agents in cases of emergency requiring immediate
attention.
(9) Optometric
physicians certified for nontopical TPA with injections (ATI) use may
administer subcutaneous and subconjunctival injections. Sub-Tenon, retrobulbar,
intraocular and botulinum toxin injections are excluded.
(10) Optometric physicians certified for
nontopical TPA use, may administer oral pre-medication for light sedation.
Conscious sedation, deep sedation and general anesthesia are
excluded.
(11) Optometric
physicians certified for topical or nontopical TPA use may prescribe and
dispense therapeutic contact lenses that include pharmaceutical agents listed
on the topical formulary in OAR 852-80-0020.
Notes
Stat. Auth.: ORS 683 & 182
Stats. Implemented: ORS 683.240, 683.270 & 182.466
State regulations are updated quarterly; we currently have two versions available. Below is a comparison between our most recent version and the prior quarterly release. More comparison features will be added as we have more versions to compare.
No prior version found.